In recent developments, pharmaceutical company Celltrion has reportedly reached a resolution in its settlement with Johnson & Johnson (J&J) in the United States. The settlement pertains to CT-P43, Celltrion’s biosimilar to J&J’s STELARA®, more technically known as Ustekinumab.
Under the terms of the settlement, Celltrion is permitted to launch the product on the U.S. market on the 7th of March, 2025. However, it is important to note that this is contingent upon the product being approved by the U.S. Food and Drug Administration (FDA) ahead of the projected launch date.
The product in question, Ustekinumab, is a human monoclonal antibody, designed to reduce the effects of a substance in the body which can cause inflammation. It is used in adults to treat psoriasis, psoriatic arthritis, and Crohn’s disease. These are all conditions that result in the patient experiencing uncomfortable and, at times, painful inflammation.
Celltrion’s decision to create a biosimilar simpler to the successful STELARA medicine indicates a strategic focus on expanding their reach within the biopharmaceutical industry.
More details on this settlement are likely to emerge as the 2025 launch date approaches and the approval process with the FDA progresses. It will undoubtedly be a key event to watch for both legal professionals and pharmaceutical companies alike, setting precedents for future cases involving biosimilars.
Much of the information provided here, as well as updates to the story, can be found on JDSupra.